#	Pagina
attuale pagina	/open-h2020/projects/217495/index.html

Opendata, web and dolomites

MEsHH SIGNED

DNA MEthylation for HPV-related disease among women living with HIV

Total Cost €

EC-Contrib. €

Partnership

Views

MEsHH project word cloud

Explore the words cloud of the MEsHH project. It provides you a very rough idea of what is the project "MEsHH" about.

markers histological lacking cancer validation clinician performance persistence tests lesions burkina 18 epb41l3 vili methylation swabs capacity africa detection prevalent relevance bf multiplex visual hiv mal hpv16 acetic hpv enrolled lesion previously combination collected follow regression neoplasia inspection cin dna meshh stand predicting negative poor human mir shown 615 positive cadm1 overtreatment predictive incident alone data reported sensitivity cytology months ing south cervical 31 grade colposcopy lugol sa matching wlhiv cin2 n distinguish faso background genes women via prospective pyrosequencing endocervical specificity iodine screening carcinogenesis progression assays primary coverage strategies acid self performed 16 referral virus 33 living 1238 623 intraepithelial thereby

Project "MEsHH" data sheet

The following table provides information about the project.

Coordinator	FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE Organization address address: AVENIDA GRAN VIA HOSPITALET 199-203 city: L'HOSPITALET DE LLOBREGAT postcode: 8908 website: www.idibell.cat contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Spain [ES]
Total cost	158˙121 €
EC max contribution	158˙121 € (100%)
Programme	1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
Code Call	H2020-MSCA-IF-2017
Funding Scheme	MSCA-IF-EF-ST
Starting year	2018
Duration (year-month-day)	from 2018-09-05 to 2020-09-04

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE Organization address address: AVENIDA GRAN VIA HOSPITALET 199-203 city: L'HOSPITALET DE LLOBREGAT postcode: 8908 website: www.idibell.cat contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (L'HOSPITALET DE LLOBREGAT)	coordinator	158˙121.00

Map

Project objective

Background: The current screening methods for cervical cancer screening among women living with HIV (WLHIV) have previously shown high sensitivity but poor specificity for the detection of high-grade cervical intraepithelial neoplasia (CIN2), resulting in over-referral for colposcopy and overtreatment of cervical lesions that may have low potential for progression to cancer. Methylation changes of human genes or HPV DNA have been reported early in carcinogenesis but their validation for predicting CIN among WLHIV is lacking. Objectives: Among 1238 WLHIV enrolled in Burkina Faso (BF; n=615) and South Africa (SA; n=623), the MesHH study aims to evaluate the performance of the DNA methylation of human genes (CADM1, MAL, MiR and EPB41L3) and HPV (HPV16/18/31/33) for the detection of prevalent and incident CIN2 compared to, or in combination with, other screening methods (visual inspection using acetic acid [VIA] or Lugol’s iodine [VILI], cytology and HPV DNA) and to evaluate the capacity of the DNA methylation markers to distinguish cervical lesion progression, persistence or regression at 16 months follow-up. Methods: The study will use endocervical swabs with matching histological data collected as part of a prospective study evaluating cervical cancer screening strategies among WLHIV in BF and SA. The DNA methylation assays for human genes (CADM1, MAL, MiR, EPB41L3) and HPV (HPV16/18/31/33) will be performed using pyrosequencing assays. Sensitivity, specificity, positive and negative predictive values for the detection of CIN2 will be estimated for the various DNA methylation markers, as stand-alone or multiplex tests. Relevance: Multiplex DNA methylation assays including a combination of human genes and HPV virus may have potential as primary screening for CIN2 among WLHIV. DNA methylation assays also have the potential to be performed using the same clinician- or self-collected sample used for cytology or HPV testing, thereby increasing screening coverage.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MESHH" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MESHH" are provided by the European Opendata Portal: CORDIS opendata.